Early-Stage IVD Feasibility & Technical Risk Advisory
Independent technical input to assess assay feasibility, identify hidden risks, and define the right development path before committing time, cost, or capital.
For early-stage diagnostics startups and founders navigating key feasibility and development decisions
Support is focused on early-stage assay feasibility, performance, and development readiness - where technical uncertainty has the greatest impact.
Is this the right stage to engage Orivise?
Orivise supports early-stage diagnostics startups when feasibility is unclear, risks are not fully understood, and critical decisions cannot be made with confidence.
Feasibility Audit & "Go/No-Go" Decision Support
Independent evaluation of assay feasibility, architecture, and early performance risk before significant development investment is committed.
What’s assessed
Assay format & detection strategy
Reagent & bioconjugation approach
Identification of fundamental Feasibility gaps
Outcome
Clear recommendation: proceed, refine, or stop
Feasibility risk map highlighting key technical uncertainties
Defined performance gaps against target requirements
Prioritised next steps aligned to decision-making
Typical questions we answer:
How do I evaluate whether my assay concept will work?
What data is needed before starting IVD development?
What are the risks in early-stage assay feasibility?
Troubleshooting & Bioconjugation Strategy
Focused technical deep-dive to resolve persistent assay performance issues and unlock stalled development programs.
What’s assessed
Signal-to-noise & background interference drivers
Conjugation efficiency, orientation, & stability
Root-cause analysis of run-to-run variability
Outcome
Root-cause hypothesis for variability, sensitivity, or stability issues
Identified critical parameters impacting assay performance
Targeted experimental direction (what to test next and why)
Reduced iteration cycles through focused problem definition
Typical questions we answer:
Why is my immunoassay not reproducible?
What causes high background or poor sensitivity?
What are common bioconjugation issues in diagnostics?
Development Readiness & Tech-Transfer Audit
Assessment of whether an assay is sufficiently robust for design-controlled development or transfer to a CDMO/manufacturing partner.
What’s assessed
Robustness, reproducibility, and reagent scalability.
Design input readiness and technical file gaps.
Alignment with ISO 13485 and IVDR/FDA expectations.
Outcome
Assessment of readiness for scale-up or transfer
Identification of risks to reproducibility and robustness
Defined critical inputs and control parameters
Structured recommendations to improve development readiness
Typical questions we answer:
What should be validated before scaling up an IVD assay?
Why do assays fail during transfer to manufacturing?
What makes an assay “development-ready”?
Not sure which path is right for your assay or programme?
Make the right technical decision before committing resources.
Initial discussion focused on your key technical decision. Confidential. No obligation.
When to Engage Orivise
Most teams don’t know if they are too early or too late to bring in external expertise.
Engage Orivise at the moments where technical uncertainty becomes commercial risk.
Early Feasibility
(Pre-Seed / Seed)
When: Before investor discussions or major grant applications
Focus: Feasibility and technical risk
Value: Build a credible, defensible technical story
Technical Due Diligence
(Series A / M&A)
When: During funding or acquisition evaluation
Focus: Independent validation of assay architecture and claims
Value: Identify hidden technical debt before capital is committed
Development Readiness
(Pre-Transfer)
When: 3–6 months before CDMO or scale-up
Focus: Robustness, reproducibility, and documentation readiness
Value: Prevent costly transfer failures and rework
Critical Troubleshooting
(R&D Bottlenecks)
When: When performance issues stall progress
Focus: Root-cause analysis of variability and instability
Value: Unblock development and restore momentum
Common Triggers for Engagement
If any of these sound familiar, it’s the right time to bring in independent technical input:
Investor requests independent technical validation
Tech transfer risk feels unclear or high
Stability or sensitivity issues are delaying milestones
Assay performance is inconsistent or not reproducible
Data does not support clear development decisions
Ready to discuss your assay or IVD concept?
Request a Feasibility & Technical Risk Review to understand feasibility, risk, and development readiness.